| 臺大學術典藏 |
2021-03-18T02:03:00Z |
Disseminated peritoneal leiomyomatosis responds to systemic chemotherapy
|
Lin Y.-C.; Wei L.-H.; CHIA-TUNG SHUN; Cheng A.-L.; Hsu C.-H. |
| 臺大學術典藏 |
2021-03-18T02:02:53Z |
Polymorphism in epidermal growth factor receptor intron 1 predicts prognosis of patients with esophageal cancer after chemoradiation and surgery
|
Lee J.-M.;Yang S.-Y.;Yang P.-W.;Chia-Tung Shun;Wu M.-T.;Hsu C.-H.;Lin C.-C.;Cheng J.-C.-H.;Wang Y.-H.;Chuang T.-H.;Chen J.-S.;Hsu H.-H.;Huang P.-M.;Kuo S.-W.;Lee Y.-C.; Lee J.-M.; Yang S.-Y.; Yang P.-W.; CHIA-TUNG SHUN; Wu M.-T.; Hsu C.-H.; Lin C.-C.; Cheng J.-C.-H.; Wang Y.-H.; Chuang T.-H.; Chen J.-S.; Hsu H.-H.; Huang P.-M.; Kuo S.-W.; Lee Y.-C. |
| 臺大學術典藏 |
2021-03-18T02:02:48Z |
Bevacizumab with erlotinib as first-line therapy in Asian patients with advanced hepatocellular carcinoma: A multicenter phase II study
|
Hsu C.-H.;Kang Y.K.;Yang T.-S.;Chia-Tung Shun;Shao Y.-Y.;Su W.-C.;Sandoval-Tan J.;Chiou T.-J.;Jin K.;Hsu C.;Cheng A.-L.; Hsu C.-H.; Kang Y.K.; Yang T.-S.; CHIA-TUNG SHUN; Shao Y.-Y.; Su W.-C.; Sandoval-Tan J.; Chiou T.-J.; Jin K.; Hsu C.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-18T02:02:23Z |
Increased Expression of Programmed Death-Ligand 1 in Infiltrating Immune Cells in Hepatocellular Carcinoma Tissues after Sorafenib Treatment
|
Lu L.-C.;Lee Y.-H.;Chang C.-J.;Chia-Tung Shun;Fang C.-Y.;Shao Y.-Y.;Liu T.-H.;Cheng A.-L.;Hsu C.-H.; Lu L.-C.; Lee Y.-H.; Chang C.-J.; CHIA-TUNG SHUN; Fang C.-Y.; Shao Y.-Y.; Liu T.-H.; Cheng A.-L.; Hsu C.-H. |
| 臺大學術典藏 |
2021-03-15T08:26:16Z |
AlGaN/GaN high electron mobility transistors for protein-peptide binding affinity study
|
Huang C.-C.; Lee G.-Y.; Chyi J.-I.; HUI-TENG CHENG; Hsu C.-P.; Hsu Y.-R.; Hsu C.-H.; Huang Y.-F.; Sun Y.-C.; Chen C.-C.; Li S.-S.; Andrew Yeh J.; Yao D.-J.; Ren F.; Wang Y.-L. |
| 臺大學術典藏 |
2021-03-15T07:44:49Z |
Metastasectomy of Krukenberg tumors may be associated with survival benefits in patients with metastatic gastric cancer
|
LI-CHUN LU; Shao Y.-Y.; Hsu C.-H.; Hsu C.; Cheng W.-F.; Lin Y.-L.; Cheng A.-L.; Yeh K.-H. |
| 臺大學術典藏 |
2021-03-15T07:44:49Z |
Increasing incidence of brain metastasis in patients with advanced Hepatocellular carcinoma in the era of Antiangiogenic targeted therapy
|
Shao Y.-Y.; LI-CHUN LU; Cheng A.-L.; Hsu C.-H. |
| 臺大學術典藏 |
2021-03-15T07:44:49Z |
Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systems
|
Shao Y.-Y.; LI-CHUN LU; Lin Z.-Z.; Hsu C.; Shen Y.-C.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-15T07:44:48Z |
�]-Catenin (CTNNB1) mutations are not associated with prognosis in advanced hepatocellular carcinoma
|
LI-CHUN LU; Shao Y.-Y.; Lee Y.-H.; Hsieh M.-S.; Hsiao C.-H.; Lin H.-H.; Kao H.-F.; Ma Y.-Y.; Yen F.-C.; Cheng A.-L.; Hsu C.-H. |
| 臺大學術典藏 |
2021-03-15T07:44:48Z |
Hospital volume of percutaneous radiofrequency ablation is closely associated with treatment outcomes for patients with hepatocellular carcinoma
|
LI-CHUN LU; Shao Y.-Y.; Kuo R.N.C.; Lin Z.-Z.; Yeh Y.-C.; Shau W.-Y.; Hsu C.-H.; Cheng A.-L.; Lai M.-S. |
| 臺大學術典藏 |
2021-03-15T07:44:47Z |
Prognosis of patients with advanced hepatocellular carcinoma who failed first-line systemic therapy
|
Shao Y.-Y.; Wu C.-H.; LI-CHUN LU; Chan S.-Y.; Ma Y.-Y.; Yen F.-C.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-15T07:44:47Z |
Clinical characteristics of advanced hepatocellular carcinoma patients with prolonged survival in the era of anti-angiogenic targeted-therapy
|
LI-CHUN LU; Shao Y.-Y.; Chan S.-Y.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-15T07:44:46Z |
Tumor heterogeneity in hepatocellular carcinoma: Facing the challenges
|
LI-CHUN LU; Hsu C.-H.; Hsu C.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-15T07:44:46Z |
Tumor-associated neutrophils: An emerging player in the immune microenvironment of hepatocellular carcinoma
|
LI-CHUN LU; Hsu C.-H. |
| 臺大學術典藏 |
2021-03-15T07:44:46Z |
Treatment efficacy differences of sorafenib for advanced hepatocellular carcinoma: A meta-analysis of randomized clinical trials
|
Shao Y.-Y.; Shau W.-Y.; Chan S.-Y.; LI-CHUN LU; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-15T07:44:45Z |
Prescription patterns of sorafenib and outcomes of patients with advanced hepatocellular carcinoma: A national population study
|
Li-Chun Lu;Chen P.-J.;Yeh Y.-C.;Hsu C.-H.;Chen H.-M.;Lai M.-S.;Shao Y.-Y.;Cheng A.-L.; LI-CHUN LU; Chen P.-J.; Yeh Y.-C.; Hsu C.-H.; Chen H.-M.; Lai M.-S.; Shao Y.-Y.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-15T07:44:45Z |
Inhibition of the Wnt/�]-catenin signaling pathway improves the anti-tumor effects of sorafenib against hepatocellular carcinoma
|
Lin H.-H.; Feng W.-C.; LI-CHUN LU; Shao Y.-Y.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-15T07:44:44Z |
Targeting tumor-infiltrating Ly6G+ myeloid cells improves sorafenib efficacy in mouse orthotopic hepatocellular carcinoma
|
Chang C.-J.;Yang Y.-H.;Chiu C.-J.;Li-Chun Lu;Liao C.-C.;Liang C.-W.;Hsu C.-H.;Cheng A.-L.; Chang C.-J.; Yang Y.-H.; Chiu C.-J.; LI-CHUN LU; Liao C.-C.; Liang C.-W.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-15T07:44:44Z |
Considerations of heterogeneity in clinical trials for hepatocellular carcinoma
|
Liu T.-H.;Shao Y.-Y.;Li-Chun Lu;Shen Y.-C.;Hsu C.;Lin Z.-Z.;Hsu C.-H.;Cheng A.-L.; Liu T.-H.; Shao Y.-Y.; LI-CHUN LU; Shen Y.-C.; Hsu C.; Lin Z.-Z.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-15T07:44:44Z |
Increased Expression of Programmed Death-Ligand 1 in Infiltrating Immune Cells in Hepatocellular Carcinoma Tissues after Sorafenib Treatment
|
Li-Chun Lu;Lee Y.-H.;Chang C.-J.;Shun C.-T.;Fang C.-Y.;Shao Y.-Y.;Liu T.-H.;Cheng A.-L.;Hsu C.-H.; LI-CHUN LU; Lee Y.-H.; Chang C.-J.; Shun C.-T.; Fang C.-Y.; Shao Y.-Y.; Liu T.-H.; Cheng A.-L.; Hsu C.-H. |
| 臺大學術典藏 |
2021-03-15T07:44:43Z |
Early alpha-foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma
|
Shao Y.-Y.;Liu T.-H.;Hsu C.;Li-Chun Lu;Shen Y.-C.;Lin Z.-Z.;Cheng A.-L.;Hsu C.-H.; Shao Y.-Y.; Liu T.-H.; Hsu C.; LI-CHUN LU; Shen Y.-C.; Lin Z.-Z.; Cheng A.-L.; Hsu C.-H. |
| 臺大學術典藏 |
2021-03-15T07:44:43Z |
Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
|
Li-Chun Lu;Hsu C.;Shao Y.-Y.;Chao Y.;Yen C.-J.;Shih I.-L.;Hung Y.-P.;Chang C.-J.;Shen Y.-C.;Guo J.-C.;Liu T.-H.;Hsu C.-H.;Cheng A.-L.; LI-CHUN LU; Hsu C.; Shao Y.-Y.; Chao Y.; Yen C.-J.; Shih I.-L.; Hung Y.-P.; Chang C.-J.; Shen Y.-C.; Guo J.-C.; Liu T.-H.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-15T07:44:42Z |
Solving the deficit of cancer pain management skills by education programs
|
Shao Y.-Y.; Lin W.-Y.; Lin C.-P.; LI-CHUN LU; Hsu C.-H. |
| 臺大學術典藏 |
2021-03-15T06:27:34Z |
Factors impacting prognosis prediction in BCLC stage C and Child-Pugh Class A hepatocellular carcinoma patients in prospective clinical trials of systemic therapy
|
Lin Z.-Z.; Hsu C.; Hu F.-C.; Shao Y.-Y.; DWANG-YING CHANG; Yang C.-H.; Hong R.-L.; Hsu C.-H.; Chengb A.-L. |
| 臺大學術典藏 |
2021-03-11T04:29:16Z |
Prescription patterns of anti-diabetic medications and clinical outcomes in Asian patients with heart failure and diabetes mellitus
|
Chia Y.M.F.;Teng T.-H.K.;Tay W.T.;Anand I.;Macdonald M.R.;Yap J.;Chandramouli C.;Richards A.M.;Tromp J.;Ouwerkerk W.;Ling L.H.;Lam C.S.P.;Hung C.-L.;Liew H.B.;Narasimhan C.;Ngarmukos T.;Park S.W.;Reyes E.;Siswanto B.B.;Shimizu W.;Zhang S.;Fan X.;Chen K.;Wu L.;Xie Y.;Jin Q.;Ling T.;Li X.;Zhou F.;Zhou Y.;Xu D.;Zhang H.;Su Y.;Chen X.;Qin S.;Wang J.;Gong X.;Wu Z.;Yu C.M.;Sastry B.K.S.;Gopi A.;Raghu K.;Sridevi C.;Kaur D.;Naik A.;Parikh K.;Chandarana A.;Shah U.;Chag M.;Baxi H.;Gupta S.;Bhatia J.;Khakhkhar V.;Sankhla V.;Patel T.;Kapoor V.;Wander G.S.;Tandon R.;Chopra V.;Kumar M.;Sethi H.J.S.;Verma R.;Mittal S.;Sawhney J.;Sharma M.K.;Purayil M.P.;Tedjokusumo P.;Martanto E.;Erwinanto, Munawar M.;Pambudi J.A.;Lukito A.;Pardede I.;Thengker A.;Damay V.;Danny S.S.;Surarso R.;Noda T.;Nakajima I.;Wada M.;Ishibashi K.;Kurita T.;Yasuoka R.;Asai K.;Murai K.;Kubota Y.;Izumi Y.;Ikeda T.;Hisatake S.;Kabuki T.;Kiuchi S.;Hagiwara N.;Suzuki A.;Suzuki T.;Hong S.K.;Lee S.;Soo L.D.;Kim D.-H.;Shim J.;Park S.-M.;Roh S.-Y.;Kim Y.H.;Kim M.;Choi J.-I.;Na J.O.;Rha S.W.;Seo H.S.;Oh D.J.;Park C.G.;Kim E.J.;Joung B.;Uhm J.-S.;Lee M.H.;Cho I.-J.;Park H.-N.;Park H.-W.;Cho J.-G.;Yoon N.;Lee K.;Kim K.H.;Kim S.H.;Saharudin S.;Beh B.C.;Lee Y.W.;Yen C.H.;Othman M.K.;Augustine A.-A.;Asnawi M.H.M.;Mojolou R.A.;Tan Y.Z.;Arbain A.N.;Wong C.K.;Omar R.;Ghazi A.M.;Khelae S.K.;Chew D.S.P.;Yap L.B.;Hussin A.;Muhammad Z.;Azmee M.G.;Abidin I.Z.;Zhudi A.S.B.M.;Sari N.A.M.;Sridhar G.S.;Zuhdi A.S.M.;Ismail M.D.;Ong T.K.;Cham Y.L.;Khiew N.Z.;Said A.B.;Fong A.Y.Y.;Amin N.H.M.;Seng K.C.;Tan S.K.;Yew K.L.;Santos J.;Lim A.;Lapitan R.;Andal R.;Lopez E.;Sim K.L.D.;Tan B.Y.;Lim C.P.;Teo L.L.Y.;Chan L.L.H.;Chai P.;Wong C.C.R.;Poh K.K.;Yeo P.S.D.;Lee E.M.;Loh S.Y.;Ching M.E.;Khoo D.Z.L.;Yew M.S.;Huang W.;Leong K.T.G.;See J.H.J.;Lim Y.B.;Tan S.;Yeo C.;Chai S.C.;Jaufeerally F.R.;Tulsidas H.;Aung T.;Ong H.Y.;Ling L.F.;Soon D.K.N.;Yeh H.-I.;Kuo J.-Y.;Yen C.-H.;Hwang J.-J.;Chien K.-L.;Su T.-C.;Lin L.-Y.;Juang J.-M.;Lin Y.-H.;Fu-Tien Chiang;Lin J.-L.;Ho Y.-L.;Lee C.-M.;Lin P.-C.;Hung C.-S.;Chang S.-N.;Lin J.-W.;Hsu C.-N.;Yu W.-C.;Chao T.-F.;Sung S.-H.;Wang K.-L.;Leu H.-B.;Lin Y.-J.;Chang S.-L.;Huang P.-H.;Lo L.-W.;Wu C.-H.;Liang H.-Y.;Chang S.-S.;Hsiao L.-C.;Wang Y.-C.;Lu C.-R.;Wu H.-P.;Lin Y.-N.;Chen K.-W.;Lo P.-H.;Hsu C.-H.;Hsieh L.-C.;Chandavimol M.;Yingchoncharoen T.;Laothavorn P.;Tiyanon W.;Wongcharoen W.;Phrommintikul A.;On Behalf Of The Asian-Hf Investigators; Chia Y.M.F.; Teng T.-H.K.; Tay W.T.; Anand I.; MacDonald M.R.; Yap J.; Chandramouli C.; Richards A.M.; Tromp J.; Ouwerkerk W.; Ling L.H.; Lam C.S.P.; Hung C.-L.; Liew H.B.; Narasimhan C.; Ngarmukos T.; Park S.W.; Reyes E.; Siswanto B.B.; Shimizu W.; Zhang S.; Fan X.; Chen K.; Wu L.; Xie Y.; Jin Q.; Ling T.; Li X.; Zhou F.; Zhou Y.; Xu D.; Zhang H.; Su Y.; Chen X.; Qin S.; Wang J.; Gong X.; Wu Z.; Yu C.M.; Sastry B.K.S.; Gopi A.; Raghu K.; Sridevi C.; Kaur D.; Naik A.; Parikh K.; Chandarana A.; Shah U.; Chag M.; Baxi H.; Gupta S.; Bhatia J.; Khakhkhar V.; Sankhla V.; Patel T.; Kapoor V.; Wander G.S.; Tandon R.; Chopra V.; Kumar M.; Sethi H.J.S.; Verma R.; Mittal S.; Sawhney J.; Sharma M.K.; Purayil M.P.; Tedjokusumo P.; Martanto E.; Erwinanto, Munawar M.; Pambudi J.A.; Lukito A.; Pardede I.; Thengker A.; Damay V.; Danny S.S.; Surarso R.; Noda T.; Nakajima I.; Wada M.; Ishibashi K.; Kurita T.; Yasuoka R.; Asai K.; Murai K.; Kubota Y.; Izumi Y.; Ikeda T.; Hisatake S.; Kabuki T.; Kiuchi S.; Hagiwara N.; Suzuki A.; Suzuki T.; Hong S.K.; Lee S.; Soo L.D.; Kim D.-H.; Shim J.; Park S.-M.; Roh S.-Y.; Kim Y.H.; Kim M.; Choi J.-I.; Na J.O.; Rha S.W.; Seo H.S.; Oh D.J.; Park C.G.; Kim E.J.; Joung B.; Uhm J.-S.; Lee M.H.; Cho I.-J.; Park H.-N.; Park H.-W.; Cho J.-G.; Yoon N.; Lee K.; Kim K.H.; Kim S.H.; Saharudin S.; Beh B.C.; Lee Y.W.; Yen C.H.; Othman M.K.; Augustine A.-A.; Asnawi M.H.M.; Mojolou R.A.; Tan Y.Z.; Arbain A.N.; Wong C.K.; Omar R.; Ghazi A.M.; Khelae S.K.; Chew D.S.P.; Yap L.B.; Hussin A.; Muhammad Z.; Azmee M.G.; Abidin I.Z.; Zhudi A.S.B.M.; Sari N.A.M.; Sridhar G.S.; Zuhdi A.S.M.; Ismail M.D.; Ong T.K.; Cham Y.L.; Khiew N.Z.; Said A.B.; Fong A.Y.Y.; Amin N.H.M.; Seng K.C.; Tan S.K.; Yew K.L.; Santos J.; Lim A.; Lapitan R.; Andal R.; Lopez E.; Sim K.L.D.; Tan B.Y.; Lim C.P.; Teo L.L.Y.; Chan L.L.H.; Chai P.; Wong C.C.R.; Poh K.K.; Yeo P.S.D.; Lee E.M.; Loh S.Y.; Ching M.E.; Khoo D.Z.L.; Yew M.S.; Huang W.; Leong K.T.G.; See J.H.J.; Lim Y.B.; Tan S.; Yeo C.; Chai S.C.; Jaufeerally F.R.; Tulsidas H.; Aung T.; Ong H.Y.; Ling L.F.; Soon D.K.N.; Yeh H.-I.; Kuo J.-Y.; Yen C.-H.; Hwang J.-J.; Chien K.-L.; Su T.-C.; Lin L.-Y.; Juang J.-M.; Lin Y.-H.; FU-TIEN CHIANG; Lin J.-L.; Ho Y.-L.; Lee C.-M.; Lin P.-C.; Hung C.-S.; Chang S.-N.; Lin J.-W.; Hsu C.-N.; Yu W.-C.; Chao T.-F.; Sung S.-H.; Wang K.-L.; Leu H.-B.; Lin Y.-J.; Chang S.-L.; Huang P.-H.; Lo L.-W.; Wu C.-H.; Liang H.-Y.; Chang S.-S.; Hsiao L.-C.; Wang Y.-C.; Lu C.-R.; Wu H.-P.; Lin Y.-N.; Chen K.-W.; Lo P.-H.; Hsu C.-H.; Hsieh L.-C.; Chandavimol M.; Yingchoncharoen T.; Laothavorn P.; Tiyanon W.; Wongcharoen W.; Phrommintikul A.; on behalf of the ASIAN-HF Investigators |
| 臺大學術典藏 |
2021-03-10T05:34:20Z |
Weekly 24-hour infusional 5-fluorouracil as initial treatment for advanced gastric cancer with acute disseminated intravascular coagulation
|
Ta-Chen Huang; Yeh K.-H.; Cheng A.-L.; Hsu C.-H. |
| 臺大學術典藏 |
2021-03-10T05:34:20Z |
Phase II study of weekly vinorelbine and 24-h infusion of high-dose 5-fluorouracil plus leucovorin as first-line treatment of advanced breast cancer
|
Yeh K.H.; Lu Y.S.; Hsu C.H.; Lin J.F.; Chao H.J.; Ta-Chen Huang; Chung C.Y.; Chang C.S.; Yang C.H.; Cheng A.L. |
| 臺大學術典藏 |
2021-03-10T05:34:19Z |
Systematic review and network meta-analysis: Neoadjuvant chemoradiotherapy for locoregional esophageal cancer
|
Ta-Chen Huang; Hsu C.-H.; Lin C.-C.; Tu Y.-K. |
| 臺大學術典藏 |
2021-03-10T05:34:19Z |
Prognostic factors of metastatic or recurrent esophageal squamous cell carcinoma in patients receiving three-drug combination chemotherapy
|
Chen W.-W.; Lin C.-C.; Ta-Chen Huang; Cheng A.-L.; Yeh K.-H.; Hsu C.-H. |
| 臺大學術典藏 |
2021-03-10T05:34:19Z |
Postchemoradiotherapy pathologic stage classified by the American joint committee on the cancer staging system predicts prognosis of patients with locally advanced esophageal squamous cell carcinoma
|
Guo J.-C.; Ta-Chen Huang; Lin C.-C.; Hsieh M.-S.; Chang C.-H.; Huang P.-M.; Lee J.-M.; Hsu F.-M.; Cheng J.C.-H.; Wang H.-P.; Yeh K.-H.; Cheng A.-L.; Hsu C.-H. |
| 臺大學術典藏 |
2021-03-10T05:34:18Z |
Number of resected lymph nodes and survival of patients with locally advanced esophageal squamous cell carcinoma receiving preoperative chemoradiotherapy
|
Guo J.-C.; Lin C.-C.; Ta-Chen Huang; Huang P.-M.; Kuo H.-Y.; Chang C.-H.; Wang C.-C.; Cheng J.C.-H.; Yeh K.-H.; Hsu C.-H.; Lee J.-M. |
| 臺大學術典藏 |
2021-03-10T05:34:18Z |
On predicting clinical response to chemoradiotherapy in esophageal squamous cell carcinoma: Additional evaluation by magnetic resonance imaging may help
|
Ta-Chen Huang; Hsu C.-H. |
| 臺大學術典藏 |
2021-03-10T05:34:17Z |
Neutrophil-to-lymphocyte Ratio and Use of Antibiotics Associated With Prognosis in Esophageal Squamous Cell Carcinoma Patients Receiving Immune Checkpoint Inhibitors
|
Guo J.-C.; Lin C.-C.; Lin C.-Y.; Hsieh M.-S.; Kuo H.-Y.; Lien M.-Y.; Shao Y.-Y.; Ta-Chen Huang; Hsu C.-H. |
| 臺大學術典藏 |
2021-03-10T05:34:17Z |
Phase II study of metabolic response to one-cycle chemotherapy in patients with locally advanced esophageal squamous cell carcinoma
|
Ta-Chen Huang; Lin C.-C.; Wu Y.-C.; Chia-Hsien Cheng J.; Lee J.-M.; Wang H.-P.; Huang P.-M.; Hsu F.-M.; Yeh K.-H.; Cheng A.-L.; Tzen K.-Y.; Hsu C.-H. |
| 臺大學術典藏 |
2021-03-09T06:46:18Z |
A phase II study of weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin (HDFL) in the treatment of recurrent or metastatic colorectal cancers
|
Yeh K.-H.;Cheng A.-L.;Lin M.-T.;Ruey-Long Hong;Hsu C.-H.;Lin J.-F.;Chang K.-J.;Lee P.-H.;Chen Y.-C.; Yeh K.-H.; Cheng A.-L.; Lin M.-T.; RUEY-LONG HONG; Hsu C.-H.; Lin J.-F.; Chang K.-J.; Lee P.-H.; Chen Y.-C. |
| 臺大學術典藏 |
2021-03-09T06:46:15Z |
Prognostic value of multidrug resistance 1, glutathione-S-transferase-�k and p53 in advanced nasopharyngeal carcinoma treated with systemic chemotherapy
|
Hsu C.-H.;Chen C.-L.;Ruey-Long Hong;Chen K.-L.;Lin J.-F.;Cheng A.-L.; Hsu C.-H.; Chen C.-L.; RUEY-LONG HONG; Chen K.-L.; Lin J.-F.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-09T06:46:06Z |
Factors impacting prognosis prediction in BCLC stage C and Child-Pugh Class A hepatocellular carcinoma patients in prospective clinical trials of systemic therapy
|
Lin Z.-Z.; Hsu C.; Hu F.-C.; Shao Y.-Y.; Chang D.-Y.; Yang C.-H.; RUEY-LONG HONG; Hsu C.-H.; Chengb A.-L. |
| 臺大學術典藏 |
2021-03-09T05:18:40Z |
Weekly gemcitabine plus 24-h infusion of high-dose 5-fluorouracil/ leucovorin for locally advanced or metastatic carcinoma of the biliary tract
|
Hsu C.; Ying-Chun Shen; Yang C.-H.; Yeh K.-H.; Lu Y.-S.; Hsu C.-H.; Liu H.-T.; Li C.-C.; Chen J.-S.; Wu C.-Y.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-09T05:18:37Z |
Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma
|
Hsu C.-H.; Ying-Chun Shen; Lin Z.-Z.; Chen P.-J.; Shao Y.-Y.; Ding Y.-H.; Hsu C.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-09T05:18:36Z |
Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma
|
Shao Y.-Y.; Lin Z.-Z.; Hsu C.; Ying-Chun Shen; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-09T05:18:35Z |
Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil
|
Hsu C.-Y.; Ying-Chun Shen; Yu C.-W.; Hsu C.; Hu F.-C.; Hsu C.-H.; Chen B.-B.; Wei S.-Y.; Cheng A.-L.; Shih T.T.-F. |
| 臺大學術典藏 |
2021-03-09T05:18:34Z |
High circulating endothelial progenitor levels associated with poor survival of advanced hepatocellular carcinoma patients receiving sorafenib combined with metronomic chemotherapy
|
Shao Y.-Y.; Lin Z.-Z.; Chen T.-J.; Hsu C.; Ying-Chun Shen; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-09T05:18:33Z |
Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systems
|
Shao Y.-Y.; Lu L.-C.; Lin Z.-Z.; Hsu C.; Ying-Chun Shen; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-09T05:18:31Z |
Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
|
Lu L.-C.; Hsu C.; Shao Y.-Y.; Chao Y.; Yen C.-J.; Shih I.-L.; Hung Y.-P.; Chang C.-J.; Ying-Chun Shen; Guo J.-C.; Liu T.-H.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-09T05:18:31Z |
Considerations of heterogeneity in clinical trials for hepatocellular carcinoma
|
Liu T.-H.; Shao Y.-Y.; Lu L.-C.; Ying-Chun Shen; Hsu C.; Lin Z.-Z.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-09T05:18:30Z |
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS�VESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO
|
Chen L.-T.; Martinelli E.; Cheng A.-L.; Pentheroudakis G.; Qin S.; Bhattacharyya G.S.; Ikeda M.; Lim H.-Y.; Ho G.F.; Choo S.P.; Ren Z.; Malhotra H.; Ueno M.; Ryoo B.-Y.; Kiang T.C.; Tai D.; Vogel A.; Cervantes A.; Lu S.-N.; Yen C.-J.; Huang Y.-H.; Chen S.-C.; Hsu C.; Ying-Chun Shen; Tabernero J.; Yen Y.; Hsu C.-H.; Yoshino T.; Douillard J.-Y. |
| 臺大學術典藏 |
2021-03-09T05:18:29Z |
A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy
|
Lin Z.-Z.; Chen B.-B.; Hung Y.-P.; Huang P.-H.; Ying-Chun Shen; Shao Y.-Y.; Hsu C.-H.; Cheng A.-L.; Lee R.-C.; Chao Y.; Hsu C. |
| 臺大學術典藏 |
2021-03-05T06:07:25Z |
Induction chemotherapy with gemcitabine, oxaliplatin, and 5-fluorouracil/leucovorin followed by concomitant chemoradiotherapy in patients with locally advanced pancreatic cancer: A Taiwan cooperative oncology group phase II study
|
Ch'Ang H.-J.; Lin Y.-L.; Wang H.-P.; Chiu Y.-F.; MING-CHU CHANG; Hsu C.-H.; Tien Y.-W.; Chen J.-S.; Hsieh R.-K.; Lin P.-W.; Shan Y.-S.; Cheng A.-L.; Chang J.-Y.; Whang-Peng J.; Hwang T.-L.; Chen L.-T. |
| 臺大學術典藏 |
2021-03-04T07:50:46Z |
Inhibiting autophagy potentiates the antitumor efficacy of Euphorbia royleana for canine mammary gland tumors
|
Huang, Y.-Y.;Chen, C.-H.;Hsu, C.-H.;Kuo, T.-Y.;Liu, C.-C.;Liao, A.T.-C.;Liao, A.T.-C.;Lin, C.-S.;Lin, C.-S.; Huang, Y.-Y.; Chen, C.-H.; Hsu, C.-H.; Kuo, T.-Y.; Liu, C.-C.; Liao, A.T.-C.; Liao, A.T.-C.; Lin, C.-S.; Lin, C.-S.; CHEN-SI LIN |
| 臺大學術典藏 |
2021-03-04T02:36:03Z |
Prognostic Factors for Metastatic Urothelial Carcinoma Treated with Cisplatin and 5-Fluorouracil-Based Regimens
|
Lin C.-C.;Hsu C.-H.;Huang C.-Y.;Yu-Chieh Tsai;Huang K.-H.;Cheng A.-L.;Pu Y.-S.; Lin C.-C.; Hsu C.-H.; Huang C.-Y.; YU-CHIEH TSAI; Huang K.-H.; Cheng A.-L.; Pu Y.-S. |
